Da Volterra
Annie Ducher has extensive experience in clinical development, currently serving as Head of Clinical Development and Chief Medical Officer at Da Volterra since 2010. Prior to this role, Annie held the position of Senior Director of Clinical Development at Novexel from April 2009 to August 2010, focusing on the clinical development of key programs in the biotechnology sector. Additionally, Annie worked as Director of Clinical Development at GSK from May 2005 to April 2009. Annie holds a Doctorat in Medicine from University Paris V.
This person is not in any teams
Da Volterra
Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field. Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases. We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives. Committed to innovation, Da Volterra develops products intended to protect the intestinal microbiota or harness its potential to help prevent and cure human diseases. Over the years since inception, we have gathered a unique in-house expertise on the intestinal microbiota and its links to the different body functions, antibacterial drugs and other drugs disrupting the microbiota as well as drug delivery technologies.